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ABSTRACT Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) was recognized worldwide during
the 1990s; in less than a decade, several genetically distinct CA-MRSA lineages carrying Panton-Valentine leukocidin genes have
emerged on every continent. Most notably, in the United States, the sequence type 18-IV (ST8-IV) clone known as USA300 has
become highly prevalent, outcompeting methicillin-susceptible S. aureus (MSSA) and other MRSA strains in both community
and hospital settings. CA-MRSA bacteria are much less prevalent in Europe, where the European ST80-IV European CA-MRSA
clone, USA300 CA-MRSA strains, and other lineages, such as ST22-IV, coexist. The question that arises is whether the USA300
CA-MRSA present in Europe (i) was imported once or on very few occasions, followed by a broad geographic spread, anticipat-
ing an increased prevalence in the future, or (ii) derived frommultiple importations with limited spreading success. In the pres-
ent study, we applied whole-genome sequencing to a collection of French USA300 CA-MRSA strains responsible for sporadic
cases andmicro-outbreaks over the past decade and United States ST8MSSA andMRSA isolates. Genome-wide phylogenetic
analysis demonstrated that the population structure of the French isolates is the product of multiple introductions dating back
to the onset of the USA300 CA-MRSA clone in North America. Coalescent-based demography of the USA300 lineage shows that a
strong expansion occurred during the 1990s concomitant with the acquisition of the arginine catabolic mobile element and anti-
biotic resistance, followed by a sharp decline initiated around 2008, reminiscent of the rise-and-fall pattern previously observed
in the ST80 lineage. A future expansion of the USA300 lineage in Europe is therefore very unlikely.
IMPORTANCE To trace the origin, evolution, and dissemination pattern of the USA300 CA-MRSA clone in France, we sequenced
a collection of strains of this lineage from cases reported in France in the last decade and compared themwith 431 ST8 strains
from the United States. We determined that the French CA-MRSAUSA300 sporadic andmicro-outbreak isolates resulted from
multiple independent introductions of the USA300 North American lineage. At a global level, in the transition from anMSSA
lineage to a successful CA-MRSA clone, it first became resistant to multiple antibiotics and acquired the arginine catabolic mo-
bile element and subsequently acquired resistance to fluoroquinolones, and these two steps were associated with a dramatic de-
mographic expansion. This expansion was followed by the current stabilization and expected decline of this lineage. These find-
ings highlight the significance of horizontal gene acquisitions and point mutations in the success of such disseminated clones
and illustrate their cyclic and sporadic life cycle.
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Staphylococcus aureus remains one of the most challenging andcostly sources of bacterial infection worldwide. It asymptom-
atically colonizes about one-third of the human population and
may cause infections with outcomes that range from mild to se-
vere and are occasionally life threatening (1). Notably, it is the
most common causative agent of nosocomial infections and a
leading cause of death in hospitalized patients (2). Until the mid-
1990s, methicillin-resistant S. aureus (MRSA) infections were re-
ported exclusively in hospital settings and most hospital-
associated MRSA (HA-MRSA) diseases resulted from a limited
number of successful clones (3). However, in the beginning of the
2000s, MRSA infections began to be reported in healthy individ-
uals without risk factors or discernible connections to health care
institutions (4, 5). These community-acquired MRSA (CA-
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MRSA) strains had genetic backgrounds distinct from those of
traditional HA-MRSA strains. Moreover, international strains of
CA-MRSA belonged to a series of different lineages and specific
clones were predominant on different continents (6). The domi-
nant CA-MRSA clone in the United States, referred to as the
USA300 North American (USA300-NA) MRSA clone in this
study, belongs to pandemicmultilocus sequence type 8 (ST8) con-
stituted by methicillin-susceptible S. aureus (MSSA) and MRSA
strains with the same pulsed-field gel electrophoresis type,
USA300. This epidemiologically successful clone carries the IVa
subtype of the staphylococcal cassette chromosome mec (SCCmec)
element, agr allele 1, arginine catabolic mobile element (ACME)
type I, and a set of virulence genes including lukS-PV/lukF-PV, sek,
and seq (7–10).
It is generally recognized that this USA300-NA MRSA clone
descended from an ancestral USA500-like MSSA strain by the
acquisition of various mobile genetic elements (MGEs) and
shows very recent clonal expansion (2, 11). These MGEs,
namely, SCCmec type IV carrying themecA gene, S. aureus patho-
genicity island 5 containing sek and seq, phage phiSA2 carrying the
Panton-Valentine leukocidin genes, and ACME type I, are
thought to contribute to the success and high virulence of the
commonly known USA300-NA MRSA strains (12–16). ACME
type I is found exclusively in the USA300-NAMRSA lineage (16–
21). It has been shown that the functional modularity (arginine
deiminase system [arc] and the speG gene, which encodes a poly-
amine resistance enzyme) plays a major role in the enhanced suc-
cess of this clone during colonization and skin infections (22, 23).
In recent years, multiple studies have shown that the USA300-NA
MRSA clone has spread worldwide, with reports of outbreaks in
South America, the Middle East, the western Pacific, and Europe
(for a detailed review, see reference 24). Interestingly, in South
America, the most prevalent CA-MRSA is a USA300 variant, the
so-called Latin American variant or USA300-LV (i.e., ST8, spa
type t008, SCCmec type IVc, lukSF-PV, arcA) present in Colom-
bia, Venezuela, and Ecuador (24–26). It has recently been pro-
posed that the USA300MRSA lineage has evolved since the 1980s
into two parallel epidemics, one in North America with the acqui-
sition of the ACME by the ancestral USA300 lineage, forming the
USA300-NAMRSA epidemic, and one in SouthAmerica, with the
acquisition of a novel copper and mercury resistance (COMER)
element by the ancestral lineage (27).
In Europe, CA-MRSA epidemiology is characterized by clonal
heterogeneity, although the most common European strain is the
European clone (ST80-IV, pvl) (28). This clone originally
emerged from a West African ancestor (29) and expanded in the
Mediterranean area, the Middle East, and North Africa, as many
of the first patients infectedwith this clone in Europe had histories
of travel to these regions. Although the prevalence of this “Euro-
pean” clone is relatively high in some countries, like Algeria and
Tunisia, with a widespread distribution in both hospital and com-
munity settings (28–30), in Europe, the prevalence of this clone, as
well as that of CA-MRSA in general, remains low (31, 32) and even
seems to be declining (33, 34). This decay is in keeping with the
calculation of a recent slow decrease in its effective population size
based on a Bayesian skyline model (29). However, the question
arose as to whether the CA-MRSA clone (USA300-NA or
USA300-LV) could replace ST80 CA-MRSA and expand in a wor-
risome scenario similar to the one observed in theUnited States in
the past decade. Consistent with this hypothesis is the fact that the
USA300-NAMRSA clone has been reported to be present inmany
European countries for several years (31, 32, 35–45) and is occa-
sionally associated with infection clusters (46–48). A recent study
showed that an increase in CA-MRSAUSA300 prevalence in 2013
in Geneva, Switzerland, was due to distinct importations from the
North and South American continents (49).
This study addressed the question of the USA300 lineage’s ca-
pacity to expand successfully in Europe by applying whole-
genome sequencing to a collection of French USA300 CA-MRSA
strains responsible for sporadic cases, as well as micro-outbreaks,
over the past decade, followed by a comparison with available
genomes of USA300 CA-MRSA, USA300MSSA strains, and other
ST8 isolates from the United States (50, 51). Genome-wide phy-
logenetic relationships and coalescent-based analyses showed that
the population structure of the French isolates reflects multiple
introductions of the USA300-NA MRSA clone. Furthermore, the
coalescent-based demography of USA300-NA lineage confirmed
its success in the late 1990s but also suggested a sharp decline
initiated around 2008, reminiscent of the rise-and-fall pattern ob-
served in the ST80 lineage.
RESULTS
USA300 phylogeography and resistance makeup. Prior to phy-
logenetic reconstruction, we checked if the data set provided some
evidence of homologous recombination. We first made a visual
inspection of the concatenated single-nucleotide polymorphisms
(SNPs), and no contiguous SNPs consisting of three or more
SNPs, mirroring homologous recombination, were detected. In a
second step, neighbor nets were inferred in order to detect puta-
tive recombination signatures that would result in networks
rather than trees. No major splits were found, and the pairwise
homoplasy index (PHI) test failed to detect recombination signa-
tures (P  0.475). We then performed whole-genome phyloge-
netic analysis of the 498 ST8 isolates (includingMRSA,MSSA, and
USA300-LV and USA300-NA MRSA isolates) obtained from
France (n  67) and the United States (n  431) within a time
span of 15 years (see Table S1 in the supplemental material). A
total of 12,840 SNPswere used to generate amaximum-likelihood
(ML) tree that shows, as previously reported, that strains fromSan
Diego (51) and New York City (50) are interspersed (Fig. 1). The
closest relative sister group of the USA300-NA lineage corre-
sponded to seven strains, all isolated from theNewYork City area.
These seven isolates carry the COMER element characteristic of
the USA300-LV South American clade (27) and belong to this
lineage. Adding French USA300 CA-MRSA strains to the phylo-
genetic analysis did not unravel any new branching pattern or
hidden sublineages and revealed that all of the French isolates
belong to the USA300-NA lineage. Among the U.S. isolates, a
fluoroquinolone-resistant lineage with the same mutations in
gyrA (Ser84Leu) and parC (Ser80Tyr) has emerged within the
USA300-NA MRSA clone and disseminated globally (Fig. 1). We
observed a similar distribution in France, with 18 fluoroquinolone-
susceptible strains, including10 fromanoutbreak inLePuy-en-Velay
(a town in central France) (47) and 46 resistant isolates, including
the 28 isolates from an outbreak in a long-term care facility (Paris
16th District) showing the same two mutations in the gyrA and
parC loci. Plasmid analysis showed that all except three French
isolates carry plasmids related to previously described plasmid
p18805-p03 (52). This plasmid encodes multiple antibiotic and
heavy metal resistance genes [aminoglycosides, ant(6)-Ia and
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aph(3=)-III; beta-lactams, blaZ; macrolides mph(C); macrolides-
lincosamides-streptogramin B, msr(A); cadmium, cadD and
cadX]. These plasmids showed almost 100% nucleotide se-
quence identity indicative of a single origin but different re-
gions of deletion. Similar plasmids are also present in the vast
majority of the American isolates (50, 51) but absent from the
strains of the USA300-LV lineage. It is therefore likely that an
ancestor of this multiresistance plasmid was acquired by the
common ancestor of the USA300-NA clone and contributed to
its expansion. The 28 isolates from the outbreak in a long-term
care facility (Paris 16th District) carried in their chromosome a
3.2-kb transposable element containing the dfrG gene, which
encodes a dihydrofolate reductase conferring trimethoprim re-
sistance.
Temporal Bayesian analysis reveals the complexity of
USA300 demography. In a second step, we used the Bayesian co-
ST20130139@2013
ERS092927@2010
ST20091284@2009
FPR3757@2000
ERS093117@2010
ERS093011@2010
ERS195416@2010ERS093010@2010ERS093020@2007ERS093018@2010
ERS093035@2010
ERS093042@2010
ERS092769@2009
ERS092779@2009
ERS092924@2010
ERS092925@2009
HT20030207@2002HT20030204@2002
ERS092981@2010
ERS092766@2009
ERS092773@2009
ERS092765@2009
RCH I35@2005
ERS092971@2010
ERS092870@2009
RCH S35@2005
RCH I58@2007
ERS092775@2009
ERS092797@2009
ERS092802@2009
RCHS36@2005
RCH I19@2003
RCH S34@2005
ERS092980
@2010
ERS092970@
2010
ERS093045
@2010
ERS093083@201
0
ERS092819@2009
ERS092817@2009
ERS195398@2
009
ERS092862@2
009
ERS093
034@20
10ERS09
3040@2
010
RCH S49
@2006
RCHI21@
2003
RCH I18@
2003
RCHS2
9@200
5RCH
S15@2
003
ERS09
2912@
2009RC
HS59@
2007
ST20
1300
70@
2013
ST20
1300
69@
2013
ST20
1300
68@
2013
ST20
1112
92@
2011
ERS09
2921@
2010ERS09
2917@
2010ERS09
2916@
2010ERS09
2920@
2009
ERS0
9291
4@20
10
ERS0
9291
3@20
10ERS09
2909
@200
9
ERS0
9285
8@20
09
ERS0
9285
9@20
09
ERS0
9277
8@2
009
RCH
 I48@
200
6
ERS
092
963
@20
10
ERS
092
962
@20
10
ERS
092
961
@20
10
ERS
092
959
@20
10
ST2
011
175
5@
201
1
ERS
092
935
@20
10
ERS
092
931
@20
10
ERS
092
930
@20
10
RCH
 I42
@2
006
RCH
 I59
@2
007
RCH
I29
@2
005
ERS
093
105
@2
011
RCH
S57
@2
007
RCH
S20
@2
003
RCH
 S2
1@
200
3
RC
HI4
9@
200
6
RC
H I
38@
200
6
ERS
092
891
@2
009
ERS
092
890
@2
009
ER
S0
93
10
2@
20
11
ER
S0
93
10
3@
20
10
ER
S0
93
06
2@
20
11
ER
S1
95
41
8@
20
10
ER
S09
30
33
@2
01
0
ERS
093
032
@2
010
ER
S0
93
03
9@
20
10
ER
S0
93
01
7@
20
10
ER
S0
93
06
0@
20
11
ER
S0
93
09
1@
20
10
ER
S0
93
06
1@
20
11
ER
S1
95
42
5@
20
10
ER
S0
93
05
9@
20
10
ER
S0
93
05
8@
20
10
ER
S0
92
90
1@
20
09
ER
S0
92
89
9@
20
09
ER
S0
92
82
1@
20
09
ER
S0
92
81
3@
20
09
ER
S0
92
81
4@
20
09
ER
S0
93
01
2@
20
10
ER
S0
93
00
5@
20
10
ER
S0
93
01
3@
20
10
ER
S0
92
98
6@
20
10
ER
S0
92
98
5@
20
10
ER
S0
92
98
4@
20
10
ER
S0
92
92
2@
20
10
ER
S0
92
90
2@
20
09
ER
S0
92
89
6@
20
09
ER
S1
95
40
2@
20
09
ER
S1
95
40
4@
20
09
ER
S0
92
86
9@
20
09
ER
S0
92
85
3@
20
09
ER
S0
92
85
2@
20
09
ER
S0
92
85
1@
20
09
ER
S0
92
88
4@
20
09
ER
S1
95
40
3@
20
09
ER
S0
93
02
6@
20
10
ER
S0
92
85
6@
20
09
ER
S1
95
39
7@
20
09
ER
S1
95
39
6@
20
09
ER
S1
95
39
5@
20
09
ER
S0
92
83
6@
20
09
ER
S0
92
84
1@
20
09
ER
S0
92
84
3@
20
09
ER
S0
92
87
4@
20
09
ER
S0
92
87
3@
20
09
ER
S0
92
87
9@
20
09
ER
S0
92
87
5@
20
07
ER
S0
92
98
2@
20
10
ER
S0
92
97
4@
20
10
ER
S0
92
97
2@
20
10
ER
S0
92
97
3@
20
10
ER
S1
95
42
7@
20
11
ER
S0
93
06
9@
20
11
ER
S0
93
08
4@
20
10
ER
S1
95
42
6@
20
11
ER
S0
93
06
8@
20
11
ER
S0
93
03
1@
20
10
ER
S0
93
03
0@
20
10
ER
S0
92
79
2@
20
09
ER
S0
92
78
6@
20
09
ER
S0
93
06
7@
20
11
ER
S0
93
06
6@
20
11
ER
S0
93
09
0@
20
10
ER
S0
92
99
2@
20
10
ER
S0
93
00
1@
20
10
ER
S0
92
99
3@
20
10
ER
S0
93
03
7@
20
10
390SRE
02
9@
20
10 0102
@439290SRE
90SRE
02
@8292
10
ERS195406@
2010
E
29
29
0S
R
01
02
@9
ER
49
03
90
S
@
01
02
ERS092999@2010
ERS195415@2010
ERS195414@2010
ERS092987@2010
ERS092998@2010
ERS092988@2010
ERS092926@2010
ERS092919@2009
ERS092793@2009
ERS092918@2009
ERS195392@2009
ERS092815@2009
ERS092828@2009
ERS092983@2010
ERS092975@2010
ERS092976@2010
ERS093025@2010
ERS093036@2010
ERS093022@2010
ERS195417@2010
ERS092795@2009
ERS092910@2009
ERS092829@2009
ERS092782@2009
ERS092763@2009
ERS092777@2009
ERS092762@2009
ERS092826@2009
ERS092833@2009
ERS195413@2010
ERS092964@2010
ERS092960@2010
ERS093000@2010
ERS092990@2010
ERS092989@2010
ERS092894@2009
ERS092892@2009
ERS092893@2009
ERS092854@2009
ERS092794@2009
ERS092800@2009
ERS092801@2009
ST20140293@2014
ST20131705@2013
ST20131061@2013
ST20130825@
2014
ST20130685@
2013
ST20130559@
2013
ST20130595@
2013
ST20130560@
2013
ST20130546@
2013
ST20130554@
2013
ST20130684@
2013
ST20130594@
2013
ST20130547@
2013
ST99580@
2013
ST
31
02
55
0
1@
2
31
0
ST20130550@
2012
ST20130597@
2013
ST20130556@
2013
ST20130558@
2012
ST488012@
2013
ST20130552@
2012
ST231023@
2013
ST20130553@
2012
ST20130549@
2012
ST20130555@
2012
ST20130548@
2012
ST20130596@
2012
ST20130557@
2012
ST20130593@
2012
ST20131399@
2013
ST20131398@
2013
ST20131397@
2013
ST20112231@
2011
ST20130159@2013
ST20111414@
2011
ST20120895@
2012
ST20112561@
2011
ST20111457@
2011
ERS092897@2009ERS092945@2010
ERS092943@2010
ERS092955@2010
ERS092944@2010
ERS093021@2010
ST20131284@2013
ERS093002@2010
ERS092898@2009
RCHS38@2006
ERS092863@2009
ERS092844@2009
ERS092846@2009
ERS092845@2009
ST20131763@2013ST20121100@2012ST20131739@2013ERS093014@2010ERS093006@2010ERS093004@2010
ERS093028@2010
ERS093038@2010
ERS092761@2009
ERS092772@2009
RCHS44@2006
ERS093101@2011ERS093080@2011
RCH I57@2007
ERS093116@2010ERS195400@2009
ERS195401@2009ERS092847@2009
ERS092848@2009
ERS195399@2009
ERS093114@2009
ERS092864@2009
ERS092942@2010
ERS092953@2010
ERS092941@2010
ERS093088@201
1
ERS093087@201
0
ERS092835@2009
ERS092868@2009
ERS092834@2009
ERS092867@2009
ERS195394@2009
ERS195423@2010
ERS093051@2010
ERS093052@2010
ERS195424@2010
ERS195421@2010
ERS195422@2010
ERS195420@2010
ERS093053@2010
ERS093085@2010
RCH S43@
2006
RCH I33@20
05
RCH I34@200
5
RCH S18@
2003
RCHI15@2
003
ERS092
967@20
10
ERS0929
66@201
0
ERS0929
65@2010
ERS0929
77@2010
ST20
1220
03@2
012
ERS0
9311
2@20
11
ERS0
9310
4@20
11
ERS09
3082
@201
1
ERS0
9299
4@20
10
ERS09
2991@
2010
ERS09
2811@
2010
ERS09
2812@
2009ERS19
5391@
2009
ERS09
2823@
2009
ERS092
825@2
009
ERS195
393@2
009
ERS092
824@20
09
ERS0
9304
1@2
010
HT20
0301
24@
2003
ERS
092
796
@20
09
ERS
092
904
@20
09
ERS
092
907
@20
09
ERS0
9280
3@2
009
ERS0
9279
9@2
009R
CH S
47@
2006
ER
S0
92
95
6@
20
10
ER
S0
92
95
7@
20
08
ST
20
12
15
14
@
20
12
RC
H
S3
3@
20
05
ST
20
13
07
82
@2
01
3
ST
20
12
05
58
@2
01
2
ST
20
12
05
59
@2
01
2
ST
20
13
05
20
@2
01
3
ST
20
13
05
14
@2
01
3
ST
20
12
19
49
@2
01
2
ST
20
13
01
31
@2
01
3
ST
20
12
14
89
@2
01
2
ST
20
12
06
38
@2
01
2
ST
20
12
07
16
@2
01
2
ERS
093
108
@2
011
ERS
093
113
@2
011
ERS
093
106
@2
011ERS
093
107
@2
011
ERS
093
057
@20
10
ERS
093
056
@20
10ERS
093
086
@20
10
ERS
093
049
@20
10
ERS
093
048
@20
10ERS
093
044
@20
10
ERS
092
947
@2
010
ERS
092
908
@20
09
ERS
092
954
@2
010
ERS
092
946
@2
010
ERS
195
411
@2
010
ERS
195
410
@2
010
ERS
195
428
@2
011
ERS
093
093
@2
010
ER
S09
30
70
@2
01
1
HT
20
03
02
03
@2
00
2
ER
S0
92
76
7@
20
09
ER
S0
92
85
5@
20
09
ER
S0
92
78
3@
20
09
ER
S0
92
78
7@
20
09
ER
S0
92
78
1@
20
09
ER
S0
92
78
8@
20
07
ER
S1
95
41
2@
20
10
ER
S0
92
94
9@
20
10
ER
S0
92
95
8@
20
10E
RS
09
30
81
@2
01
1
ER
S0
93
07
9@
20
11
ER
S0
93
09
6@
20
11
ER
S0
93
07
3@
20
11
ER
S0
93
11
1@
20
11
ER
S0
93
09
7@
20
11
RC
H
I36
@2
00
5ER
S0
92
86
5@
20
09
ER
S0
92
86
6@
20
09
ER
S0
92
88
7@
20
09
ER
S0
92
88
1@
20
09
ER
S0
92
87
6@
20
09
ER
S0
92
88
0@
20
09
ER
S0
93
10
0@
20
11
ER
S0
93
07
6@
20
11
ER
S0
93
07
5@
20
11
ER
S1
95
42
9@
20
11
ER
S0
92
86
1@
20
09
ER
S0
92
97
8@
20
10
ER
S0
92
97
9@
20
06
ER
S0
92
93
6@
20
10
ER
S0
92
93
2@
20
10
ER
S0
92
93
3@
20
10
ER
S0
93
09
8@
20
11
ER
S0
92
76
8@
20
09
ER
S0
92
76
0@
20
09
ER
S0
92
75
8@
20
09
ER
S0
92
91
1@
20
09
ST
20
13
03
43
@
20
13
RE
90S
03
02
@56
11
ER
90S
1102
@3603
0SRE
0102
@59039
0S
RE
29
@0
09
2
90
0
R
70
02
@6
5I
HC
ER
S1
95
40
9@
20
10
ER
S1
95
40
8@
20
10
ER
S0
92
93
8@
20
10
ER
S0
92
95
2@
20
10
ER
S1
95
40
7@
20
10
ER
S0
92
94
0@
20
10
ER
S0
92
93
7@
20
10
ER
S0
92
93
9@
20
10
ER
S0
92
77
1@
20
09
ER
S0
92
76
4@
20
09
ER
S0
92
79
0@
20
09
ER
S1
95
39
0@
20
09
ER
S0
92
78
5@
20
09
ER
S0
92
79
1@
20
07
ERS093047@
2010
90
SR
E
@3
40
3
2010
ERS093046@
2010
RCH S56@
2007
RCH S60@
2007
RCH
I44@
2006
ERS092877@
2009
ERS093089@
2010
ST20130682@
2013
ST20120553@
2012
ST20112484@
2011
ST20101834@
2010
ERS092805@
2009
ERS092995@
2010
ERS093003@
2010
ERS092784@
2009
ERS092789@
2009
ERS093071@
2011
ERS093092@
2010
ERS092857@
2009
ERS092839@
2009
ERS092840@
2009
ERS093099@
2011
ERS093007@
2010
ERS093016@
2010
ERS092798@
2009
ERS092774@
2009
ERS092818@
2009
ERS092759@
2009
HT20030206@
2002
ERS092860@2009
ERS092838@
2009
HT20010740@
2000
HT20010733@
2000
HT20010251@
2000
ERS092837@2009
ERS093027@2010
ERS092822@2009
ERS092816@2009
ERS092820@2009
ERS092895@2009
ERS092885@2009
ERS195405@2009
ERS092871@2009
ERS093110@2011
ERS093055@2010
ERS093054@2010
ERS093050@2010
ERS195419@2010
ERS093023@2010
ERS092878@2009
ERS092850@2009
ERS092948@2010
ERS093109@2011
ERS092882@2009
ERS093072@2011
ERS092889@2009
ERS092883@2009
ERS092808@2009
ERS092806@2009
ERS092969@2010
ERS092807@2009
ERS092997@2010
ERS093024@2010
ERS093009@2010
ERS093008@2010ERS092915@2010
ERS092903@2009
ERS092888@2009
ERS093015@2009
ERS092905@2009
ERS092906@2009
ERS092810@2009
ERS092809@2009
ERS092832@2009
ERS092831@2009
ERS092780@2009
ERS092770@2008
ERS092951@2010
ERS092950@2010
ERS092830@2009
ERS195389@2009
ERS092996@2010
ERS092804@2009
First circle : Fq resistance mutation
Susceptible
Resistant
Second circle : ACME
Absence
Presence
ecnatsiserniillicihteM:elcricdrihT
Susceptible
Resistant
Fourth circle : Year of isolation in blue gradients
Darkest blue (2014) Lightest blue (2000)
* * *
*
*
*
*
*
*
*
**
* Putative intercontinental transmission event
From outer to inner circle
Other ST8
USA500
Other ST8
USA300
LV USA300 NA
EREESRR19
SS
5406@
2
@@
010
STSS
20
13
TT
03
43
@
20
@@
13
FIG 1 Phylogenetic reconstruction of ST8 and its derived USA300 lineage. ML tree based on 498 genomes and a total of 12,840 concatenated SNPs, rooted by
using distantly relatedMSSA strain ERS092996. Branch colors indicate the geographic origins of the strains: red for New York State; yellow for California; green
for Minnesota, and blue for France. Outer circles represent ACME and antibiotic resistance profiles, whereas the inner circle represents the years of isolation of
the strains. The stars correspond to 12 predicted independent intercontinental USA300-NA CA-MRSA transfers from North America to France. The different
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alescent analysis implemented in BEAST (53) to generate a phy-
logenetic time tree and to derive estimated dates for the common
ancestors of the strains (see Fig. S1 in the supplemental material).
The tree was calibrated by using the sampling dates of the isolates
ranging from 2000 to 2014. We tested the performance of various
demographicmodels that favored a Bayesian skylinemodel with a
relaxed molecular clock (data not shown). The estimated short-
termmutation rate corresponded to 1.34 106 (95%confidence
interval of 1.11 106 to 1.56 106) substitutions per nucleo-
tide site per year, similar to that reported previously in USA300
MRSA (50, 54) and other S. aureus evolutionary lineages (55, 56).
On the basis of this substitution rate, the estimated time of the
most recent common ancestor (TMRCA) of the USA300-NA
clone is 1996 (see Fig. S1 in the supplemental material), a result
that slightly shifts the ancestor of the CA-MRSA clone toward the
21st century, compared to the estimates obtained by Uhlemann
and colleagues (between 1970 and 1993) (50). In addition, our
analyses revealed that the acquisition of ACME, methicillin resis-
tance, and a multiresistance plasmid dates back to 1996 and that
fluoroquinolone resistance was gained around 1998 (see Fig. S1 in
the supplemental material). It is noteworthy that, because of the
lack of intermediate strains harboring only one of those mobile
elements, we could not determine whether the acquisition of the
SCCmec element harboring the methicillin resistance gene mecA,
the multiresistance plasmid, and the ACME type I element oc-
curred simultaneously or one event occurred very shortly after the
other. The divergence with the USA300-LV MRSA South Ameri-
can lineage dates back to 1983, an estimate slightly more recent
than that proposed by Planet et al. (around 1975) (27).
We then generated a Bayesian skyline plot that estimated the
pathogen’s demographic changes over time (Fig. 2) on the basis of
the 498 ST8 genomes. The ST8 USA300 effective population size
was relatively stable from the early 1960s to the mid-1990s. Then,
a bottleneck followed, giving rise to the so-called USA300-NA
clone. Interestingly, the USA300-NA clone went through a sharp
two-phase expansion event that perfectlymatches the acquisitions
of the ACME and the antibiotic resistance elements, thus giving
rise to the USA300-NAMRSA lineage, followed by the acquisition
of fluoroquinolone resistance, as mentioned above. Strikingly,
each of these major gains of function was accompanied by a
1-order-of-magnitude population size increase, resulting in a
global 100-fold effective population size increase (Fig. 2). How-
ever, after 2008, the coalescent-based analysis detects a sharp de-
cline of the USA300-NA MRSA clone. These results need further
investigation to see if ongoing epidemiological surveys can con-
firm thismodel.We next searched for additional SNPs under pos-
itive selection that might explain the success of the USA300 lin-
eage. To address this issue, we used the PCAdapt software (57, 58)
based on a Bayesian factor model to identify candidate mutations
(Fig. 3). In Table S2 in the supplementalmaterial are shown the 20
SNPswith the highest scores (log10 Bayesian factors of6 1050).
Although such statistic-based predictions must be viewed cau-
tiously and require experimental validation, the 20 mutations
were all located in protein coding sequences (see Table S2 in the
supplemental material). The six synonymous mutations might
affect the expression of the encoded protein. Strikingly, several
mutated genes might be involved in the interaction with the
human host or the environment, as they encode surface pro-
teins, a lipoprotein, an autolysin, a putative transporter in-
volved in teichoic acid transport, and a protein involved in
lipid biosynthesis.
French isolates are interspersed in United States isolate col-
lections. Strikingly, the 67 strains in the French panel clustered in
12 lineages of 1 to 38 isolates. Furthermore, these clusters are
scattered within the North American MRSA isolates (USA300-
NA) (Fig. 1). This indicates a common origin of USA300-NA iso-
lates and European USA300 CA-MRSA isolates, likely resulting
from several transfers from the United States to Europe. Interest-
ingly, only one case could be related to travel to the United States,
in 2003 (strain HT20030124 from Annecy; see Table S1 in the
supplemental material).
We then calculated the genome-wide pairwise distances of the
most closely related French-American strains and compared them
with pairwise distances between strains collected from the same
patient at multiple sites, multiple colonies from the same nasal
sample, or strains collected from the same patient upon different
hospital admissions (59, 60) (Fig. 4). The median number of SNP
differences that separated the closest French-American epidemic
link was 74 (range, 59 to 120) and significantly differed from the
other two settings mentioned above (P 0.0001). However, this
number of differences remains smaller than the median number
of SNP differences (n 104) for USA300 CA-MRSA isolates col-
lected from different households in a New York City community
(50). In addition, bootstrap support for clades encompassing the
French strains and their closest American homologs was 70%
for 50% of the different subsamples (see Fig. S2 in the supple-
mental material). Therefore, the epidemic links we detected be-
tweenAmerican and French strains are likely to reflect direct, or at
least very short, transmission paths.
The largest French cluster contains 28 isolates from an out-
break in a Parisian long-term care facility but also 3 strains isolated
in Aubervilliers nearby Paris, as well as 6 unlinked isolates from
different parts of France (Fig. 5A and B). This cluster is very likely
the product of a single introduction from the United States. Its
TMRCA is 1998 (Fig. 5C; see Fig. S1 in the supplementalmaterial),
suggesting that this subclone had been circulating for at least a
decade in France before being noticed.
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1960 1970 1980 1990 2000 2010
101
102
103
104
E
ffe
ct
iv
e 
po
pu
la
tio
n 
si
ze
Acquisition of fluoroquinolone resistance
Acquisition of ACME
+ Methicillin resitance
1996
1998
FIG 2 Bayesian skyline plot indicating population size changes in theUSA300
lineage over time with a relaxed molecular clock. The shaded area represents
the 95% confidence interval, and the arrows point to major phenotypic events
driven byACME and antibiotic resistance thatmight have contributed directly
to the success of the USA300-NA MRSA lineage.
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DISCUSSION
Here we show that, in most instances, the USA300 CA-MRSA
cases identified in France in the last decade corresponded to spo-
radic and independent importations from the United States
(USA300-NAMRSA clone) without further indication of spread-
ing in French territory. This is consistentwith another observation
in Switzerland, where the local increased prevalence of USA300
CA-MRSA in 2013 in Geneva was shown to result from multiple
importations from America (49). As the Institut de Veille Sani-
taire (a disease surveillance agency of the Ministry of Health)
strongly recommend referring strains associated with multiple
cases of skin and soft tissue infections (SSTIs) (within a household
or other communities) to the French National Reference Lab-
oratory, it is thus likely that the lack of observed spreading truly
is due to the absence or a very limited number of secondary
cases and not to underreporting. The reasons for the apparent
lack of success of these USA300-NA CA-MRSA isolates in dif-
fusing within the French community are unknown. However, it
is in keeping with the low prevalence of CA-MRSA observed in
Europe and specifically in France (32), despite the isolation of
various CA-MRSA lineages on the European continent as early
as 1993 (38, 61). Moreover, these observations also argue
against the hypothesis that the USA300-NA MRSA clone is
intrinsically more successful than European CA-MRSA ST80
(3, 62, 63) and thus that the USA300-NAMRSA clone could be
a potential threat in Europe.
In one instance of the present study, however, one imported
lineage appeared to have a remarkable geographic spread, which
was subsequently responsible for two outbreaks, one in a long-
term care facility (Paris 16th District) and another limited out-
break in a facility for the disabled also in the Paris area (Aubervil-
liers) in 2013 and 2014 (Fig. 5A). The same lineage was also
responsible for sporadic cases scattered in French territory, i.e., in
Paris (75019, June 2011), northeastern France (Strasbourg, Janu-
ary 2013), the French Alps (Grenoble, September 2011), central
France (Orleans, January 2011), and western France (St-Nazaire,
June 2012). Our Bayesian analysis predicts a TMRCA for this
clone of 1998 (Fig. 5C). This observation suggests that introduc-
tion of the USA300-NA MRSA clone can be successful but to a
limited extent. We did not detect genes specific to this lineage or
determine which genetic mechanisms might be behind the suc-
cessful dissemination of certain isolates.
A recent report by Planet et al. (27) suggested that the history of
A B
FIG 3 SNP-based Bayesian factor model analysis for detecting genes involved in positive selection in the USA300-NA lineage. (A) Latent factors of the 12,840
SNPs and 498 strains with the first two factors. (B) Manhattan plot representing the selection scan and the outliers that are related to the different latent factors.
The dotted line highlights the top 1% of the SNPs associated with the highest Bayes factor (BF) values.
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the USA300 CA-MRSA lineage followed a parallel evolution since
the mid-1970s on the American continents; one epidemic sublin-
eage disseminated in South America (so-called USA300-LV) and
another disseminated in North America (referred to here as
USA300-NA MRSA). The separation of these two sublineages is
concomitant with the acquisition of the ACME by the North
American USA300 MRSA clone, while USA300-LV acquired an-
other mobile element—the COMER element. They also acquired,
likely independently, two different subtypes of the SCCmec ele-
ments, type IVc in the LV clade and type IVa in the NA clade. The
demography of the USA300-NA lineage based on Bayesian analy-
sis is in agreement with this model, showing a considerable demo-
graphic expansion around 1996, which coincides with the acqui-
sition of the ACME and the SCCmec element by this USA300-NA
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lineage, followed 2 years later by a second expansion peak that
likely corresponds to the acquisition of fluoroquinolone resis-
tance. This period of expansion assessed by Bayesian analysis is in
line with the observed global spread of the USA300-NA CA-
MRSA clone in North America and worldwide, although with a
more limited impact in Europe (9, 32, 35, 37, 38, 44, 45, 64–67).
Strikingly, the effective population size of the lineage is predicted
to be declining during the first decade of this century, a prediction
that should be interpreted cautiously since there is no surveillance
of the prevalence of USA300-NA CA-MRSA at the worldwide
level. However, a recent meta-analysis retrieving 1,004 publica-
tions covering the three continents showed that USA300 CA-
MRSA is far from expanding on the various continents (68) and is
instead declining in many countries (33, 34). Observations on the
European continent suggest that the USA300-NA lineage, which
has been described for decades as having a rather low prevalence
and, according to our study, was imported into France on multi-
ple instances many years ago, is apparently not expanding (32, 34,
44, 69, 70). Overall, it appears that the USA300-NA clone is be-
having like many other MRSA clones, in particular, HA-MRSA,
for which amodel of cyclic periods of expansion, equilibrium, and
decline has been observed (56, 71–76). It is worthmentioning that
in only very few cases could a plausible account be given to explain
the final population expansions, such as acquisition of resistance
to antibiotics or accumulation of mutations and increased fitness
(71–73). In the cases of USA300 CA-MRSA and the worldwide
emergence of CA-MRSA in general, there is no satisfactory expla-
nation for the concomitant emergence and expansion of the var-
ious CA-MRSA clones in different countries or on different con-
tinents at the end of the 20th century (5).
The most plausible scenario explaining CA-MRSA clone dy-
namics seems to be a complex combination of acquisition and loss
of traits under selection (resistance to antibiotics, resistance to
human host defenses), stochastic random processes, and eventu-
ally, replacement of bacterial communities by others competing
for the same niche. The latter factor might explain the population
decline observed in our Bayesian analyses; however, we have to
keep in mind that the natural habitat of S. aureus is the nose and
the skin. Therefore, focusing on population genomics of only
pathogenic lineages might blur our global understanding of spe-
cies communities and population dynamics.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains used in this study were from 24
sporadic cases that were geographically and temporally dispersed and
from three limited outbreaks reported to the French National Reference
Center for Staphylococci (CNR Staphylococci). All strains were isolated
from cases (infection and/or carriage) that occurred in continental French
territory in the past 11 years (see Table S1 in the supplemental material).
The first outbreak occurred in Le Puy en Velay, a small town located in a
rural area in Auvergne, France, and involved 12 individuals with
community-acquired SSTIs, i.e., 6 children attending the same day care
facility and 6 adult relatives in six households, between June 2011 andMay
2012 (47). Two outbreaks occurred in long-term health care units. One
was in a nursing home for mentally disabled patients in Aubervilliers in
the Paris area; four patients were detected as carriers or infected with
USA300 CA-MRSA between July 2013 and February 2014. The other out-
break occurred in a long-term care facility in the Paris 16th District be-
tween June 2012 and December 2013 and involved 10 infected patients
and 12 carriers.
Four strains from the United States corresponded to sporadic cases of
SSTIs that occurred before April 2003 and were provided by Barry Kre-
iswirth (77); three other strains originated from patients in Minnesota
before 2001 and were provided by Timothy Naimi (78). The genomic
backgrounds of these strains were assessed by diagnostic DNAmicroarray
analysis (Identibac S. aureusGenotyping; Alere, Jena, Germany) as previ-
ously described (79). This microarray covers 332 different target se-
quences corresponding to 185 distinct genes and their allelic variants. The
affiliation of isolates with clonal complexes was determined by a compar-
ison of their hybridization profiles with those of reference strains previ-
ously characterized by multilocus sequence typing (79).
Published genomic data used for comparative analysis. Genomic
data from36 isolates from the first large-scale genomic studies onUSA300
CA-MRSA were retrieved (51). These strains had been isolated between
2003 and 2007 in California. In addition, the genomic data from 387 ST8
isolates from an extensive analysis of a New York City community per-
formed between 2009 and 2011 were included. Metadata from these two
studies were graciously provided by the authors (50, 51).
DNA sequencing and SNP detection. S. aureus genomes were se-
quenced by using the Illumina HiSeq 2000 (101 nucleotide reads) or
MiSeq (150 nucleotide reads) sequencer, with a coverage of 75. Li-
braries were constructed with the Illumina TruSeq kit. Sequence reads
from previously described USA300 strains were downloaded from the
European Nucleotide Archive website (http://www.ebi.ac.uk/ena) or ob-
tained directly from the authors. Sequence reads were aligned with the
first completely sequenced and annotated US300-NA genome, FPR3757
(GenBank accession no. CP000255.1) (10) by using the Burrows-Wheeler
Alignment tool (BWA mem 0.7.5a) (80). SNP calling was done with the
Genome Analysis Toolkit (GATK 2.7-2) (81) Unified Genotyper by fol-
lowing Broad Institute best practices. Candidate SNPs were further fil-
tered by requiring coverage of greater than half of the genome mean cov-
erage and 95% read agreement to validate the call. SNPs selected with this
stringent filter were regarded as true positives andwere searched for in the
original set for every strain in which they had been filtered out. SNPs,
short indels, and coverage were visualized with SynTView (82). Specific
analysis of clones from the main French lineage was done by manually
checking read alignments around SNPs with Tablet (83). Four regions
corresponding toMGEs not present or showing a high density of SNPs in
other USA300 isolates and in closely related ST8 strains were removed
from the analysis, leaving a total of 12,840 polymorphic sites. These re-
gions are the ACME and the SCCmec cassette (41 to 125 kb), pathogenic-
ity island 3 (encoding enterotoxins K and Q; 881 to 896 kb) (84), and
integrated phages phiSA2usa (encoding the Panton-Valentine toxin;
1,546 to 1,644 kb) and phiSA3usa (2,084 to 2,127 kb). These regions
represent a total of 240 kb or 8.3% of the strain USA300_FPR3757 chro-
mosome.
Accessory genome analysis. Plasmids and chromosomal regions spe-
cific to the French isolates compared to the FPR3757 reference genome
were analyzed following de novo assembly of unmapped reads. Assembly
was performed with Velvet by using an optimized k value (85). Plasmids
and phages were identified by BLASTn searches with plasmid and phage
sequences from S. aureus as the queries. Antibiotic resistance genes were
identified with the Center for Genomic Epidemiology web tool (http://
www.genomicepidemiology.org/).
Recombination detection.Most of the analyses developed in our an-
alytical framework (phylogenetics and Bayesian inference) are based on
the assumptions that S. aureus evolution is mostly clonal and that recom-
bination can be neglected. Therefore, in a preliminary step, we tested for
the presence of mosaic genomes with the algorithm SplitsTree v4.13.1
(86). Putative recombination signatures were inferredwithNeighbor-Net
(87), and each data set was analyzed for the presence of recombinant
sequences with the PHI test in SplitsTree with an alpha value of 0.001.
Phylogenetic analyses. Phylogenic reconstructions were performed
by considering the 12,840 polymorphic sites retained in the core genome
of the 498 isolates. Phylogenetic relationships were reconstructed by the
ML approach implemented in PhyML 3.0 (88). The robustness of theML
tree topology was assessed with bootstrapping analyses of 1,000 pseu-
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doreplicated data sets. A transversion substitution model was selected on
the basis of Akaike’s information criterion with jModelTest 2.1.3 (89).
Phylogenies were rooted with MSSA strain ERS092996.
Coalescent-based analyses. Evolutionary rates and tree topologies
were analyzed with the generalized time reversible (GTR) and Hasegawa-
Kishino-Yano (90) (HKY) substitution models with gamma distributed
among-site rate variation with four rate categories (4). We tested both a
strictmolecular clock (which assumes the same evolutionary rate for all of
the branches of the tree) and a relaxed clock that allows different rates
among the branches. Constant-size, logistic, exponentially growing co-
alescent models were used. We also considered the Bayesian skyline plot
model (91), based on a general, nonparametric prior that enforces no
particular demographic history.We used a piecewise linear skyline model
with 20 groups and then compared themarginal likelihood of eachmodel
with Bayes factors estimated in Tracer 1.5. Bayes factors represent the
ratio of the marginal likelihood of the models being compared. Approxi-
mate marginal likelihoods for each coalescent model were calculated via
importance sampling (1,000 bootstrap replications) with the harmonic
mean of the sampled likelihoods. A ratio between 3 and 10 indicatesmod-
erate support of the idea that one model fits the data better than another,
whereas values of 10 indicate strong support. For each analysis, two
independent runs of 100 million steps were performed and the chain was
sampled every 10,000th generation. Examination of the Markov chain
Monte Carlo (MCMC) samples with Tracer 1.5 indicated convergence
and adequate mixing of theMarkov chains, with effective sample sizes for
each parameter in the hundreds or thousands. The first 10% of each chain
was discarded as burn-in. We found the maximum clade credibility to-
pology with TreeAnnotator 1.7.5 (52), and we reconstructed the Bayesian
skyline plot with Tracer 1.5. The relaxed clockmodels provided a better fit
to the data (Bayes factor,12) and under the different models tested, the
Bayesian skyline model provided a (marginally) better fit, overall.
Analysis of genes under positive selection. To capture SNPs under
positive selection, we used the PCAdapt software to perform a genome
scan based on a Bayesian factor model (57). We chose K  2 factors
because the third and the fourth factors did not correspond to population
structure and distinguished individuals within the same clades. The factor
analysis was performed on the centered genotype matrix that was not
scaled. The MCMC algorithm was initialized by singular value decompo-
sition, and the total number of steps was 400 with a burn-in of 200 steps.
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